Dupixent Clinical Prior Authorization Criteria Revision Effective March 15

Published on
January 14, 2021

On March 15, 2021, VDP will revise the Dupixent clinical prior authorization. Dupixent is FDA-approved for multiple indications, including the treatment of atopic dermatitis. VDP will update the current clinical prior authorization criteria for atopic dermatitis treatment to better align with the Preferred Drug List criteria. The current criteria requires a trial with a topical corticosteroid and a topical calcineurin inhibitor before Dupixent. Step 3 of the revised criteria will require prior treatments with a topical corticosteroid and crisaborole (Eucrisa®) before prescribing Dupixent.

The Dupixent clinical PA is optional for MCOs. The Pharmacy Clinical Prior Authorization Assistance Chart (PDF) shows the prior authorization each MCO uses and how those authorizations relate to the authorizations used for processing fee-for-service Medicaid claims. This chart is updated quarterly. Providers can also refer to the MCO Resources for links to each MCO's list of clinical prior authorizations.